Skip to content

Effect of intrauterine perfusion of platelet-rich plasma on patients with recurrent implantation failure and endometriosis: a prospective and non-randomized controlled study

Effect of intrauterine perfusion of platelet-rich plasma on patients with recurrent implantation failure and endometriosis: a prospective and non-randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064462
Enrollment
Unknown
Registered
2022-10-09
Start date
2022-10-08
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent implantation failure (RIF) and endometriosis (EMs)

Interventions

Group 1:intrauterine perfusion of platelet-rich plasma
Group 2:intrauterine perfusion of HCG

Sponsors

The Second People's Hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 20-40 years. 2. Patients with RIF (defined as failure of implantation in three consecutive embryo transfers of good-quality embryos, fresh or thawed, from IVF). 3. Patients with endometriosis. 4. Patients with reproductive requirements, voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Unilateral or bilateral hydrosalpinx or hydrocele; 2. Organic lesions of uterus and uterine cavity (endometrial polyps) and uterine adhesion, endometrial tuberculosis; 3. It is not suitable for the woman to get pregnant or the pregnancy will cause the aggravation of the original disease, which is life-threatening in severe cases, such as serious heart disease, nephritis, hepatitis, etc.; 4. Severe hypoplasia or deformity of the female genitalia; Have an acute infection or sexually transmitted disease; Suffering from a serious genetic, physical or psychiatric disorder; 5. Either party has serious bad habits, cognitive impairment, exposure to teratogenic radiation, poisons, drugs, and due to the action period or chromosomal karyotype abnormalities.

Design outcomes

Primary

MeasureTime frame
the implantation rate;

Secondary

MeasureTime frame
the clinical pregnancy rate;the biochemical pregnancy rate;the early miscarriage rate;the ongoing pregnancy rate;

Countries

China

Contacts

Public ContactLi Ying

The Second People's Hospital of Shenzhen

1207552176@qq.com+86 15013613327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026